SCHEMBL2371140

SCHEMBL2371140

Oc1c(C(O)c2cc(-c3cccnc3F)ccc2F)cc(Br)nc1F

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.37
ERN1 O75460 1/20 0.35
DHODH Q02127 4/20 0.35
MAPT P10636 1/20 0.34
CYP2C19 P33261 1/20 0.33
GRIA2 P42262 1/20 0.33
DYRK1A Q13627 1/20 0.32
TGFBR1 P36897 2/20 0.31
PRMT5 O14744 1/20 0.31
WDR77 Q9BQA1 1/20 0.31
CYP11B1 P15538 1/20 0.31
ALOX5AP P20292 3/20 0.30
FEN1 P39748 3/20 0.30
CSNK1A1 P48729 1/20 0.30
CSNK1D P48730 1/20 0.30
GSK3B P49841 1/20 0.30
CSNK1G2 P78368 1/20 0.30
LIPC P11150 1/20 0.30
LIPG Q9Y5X9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371164 0.70 GSK3B (0.37) CYP11B2DHODHMAPTCYP2C19GRIA2
SCHEMBL2372209 0.65 CYP11B2 (0.48) CYP11B2ERN1DHODHMAPTCYP2C19
SCHEMBL22230844 0.63 CYP11B2 (0.47) CYP11B2DHODHMAPTCYP11B1
SCHEMBL972023 0.63 CYP11B2 (0.47) CYP11B2DHODHMAPTCYP2C19GRIA2
SCHEMBL2371067 0.61 BACE1 (0.43) CYP11B2
SCHEMBL2371460 0.61 ERN1 (0.53) CYP11B2ERN1DHODHMAPTCYP2C19
SCHEMBL2371226 0.61 DHODH (0.36) CYP11B2DHODHMAPTCYP2C19GRIA2
SCHEMBL3875252 0.60 CYP11B2 (0.55) CYP11B2DHODHMAPTCYP11B1CSNK1A1
SCHEMBL23349968 0.60 KDM4E (0.39) CYP11B2ERN1DHODHMAPT
SCHEMBL3875933 0.60 CYP11B2 (0.55) CYP11B2DHODHMAPTCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP CYP11B2 1818/4885ERN1 667/4885DHODH 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.